Researchers receive over $1M to study molecular foundations of pancreatic cancer

NewsGuard 100/100 Score

Alexandros Tzatsos, M.D., Ph.D., assistant professor of anatomy and regenerative biology at the George Washington University School of Medicine and Health Sciences, was awarded over one million dollars in grants from the National Institutes of Health to study the molecular foundations of pancreatic cancer.

In May, Tzatsos received an R00 award for $706K, which is the second phase of a National Cancer Institute K99/R00 Howard Temin Pathway to Independence Award in Cancer Research - a grant meant to aid young researchers in setting up independent research labs. This grant will fund his research project, "The Role of Epigenetic Regulators in Pancreatic Cancer." In February, Tzatsos also received a $374K R21 award to fund his research project, "Elucidating and Targeting Epigenetic Oncogenic Networks in Pancreatic Cancer."

According to the American Cancer Society, pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. Few cases are found early enough for effective treatment. Tzatsos studies the role of a histone demethylase that drives the development of pancreatic cancer and he has generated new genetically engineered mouse models to address the role of this epigenetic regulator in vivo.

"We propose to use those mouse models to study pancreatic cancer and develop targeted therapies in a preclinical level," said Tzatsos. "This could be key to understand the molecular pathology of pancreatic cancer and develop better therapies."

Source: George Washington University

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases